Segment and Geographic Information (Tables)

3 Months Ended

Dec. 31, 2022

Segment Reporting [Abstract]

Financial Information for Business Segments

The following is the summary of the financial information for the Company’s reportable segments for the three months ended December 31, 2022 and 2021 (in thousands):

	Three Months Ended December 31,
	2022		2021
Revenue:
Life Sciences Products	$	89,661	$	49,877
Life Sciences Services		88,706		89,775
Total revenue	$	178,366	$	139,652
Operating income / (loss):
Life Sciences Products	$	(3,798)	$	4,388
Life Sciences Services		(4,612)		7,883
Reportable segment adjusted operating income		(8,410)		12,271
Amortization of completed technology		4,168		1,773
Purchase accounting impact on inventory		2,869		—
Amortization of other intangible assets		7,372		6,272
Restructuring charges		1,461		173
Other unallocated corporate expenses		3,405		4,378
Total operating loss		(27,685)		(325)
Interest income		10,708		35
Interest expense		(43)		(455)
Other income (expense)		1,145		(1,077)
Loss before income taxes	$	(15,875)	$	(1,822)
Assets:		Life Sciences Products		Life Sciences Services
December 31, 2022	$	886,409	$	887,310
September 30, 2022		378,790		849,603

Reconciliation of Reportable Segment Assets to Corresponding Consolidated Amounts

	December 31,		September 30,
	2022		2022
Segment assets	$	1,773,719	$	1,228,393
Cash and cash equivalents, restricted cash, and marketable securities		1,443,424		2,305,081
Deferred tax assets		298		1,169
Other assets		74,975		181,479
Total assets	$	3,292,416	$	3,716,122

Revenue from External Customers Attributed to Geographic Areas

		Three Months Ended December 31,
	2022		2021
Geographic Location:
North America	$	88,935	$	90,083
Rest of Europe		39,422		19,700
Africa		17,210		548
China		13,408		13,041
Asia Pacific/ Other		13,978		7,968
United Kingdom		5,413		8,312
Total	$	178,366	$	139,652